Non Small Cell Lung Cancer News and Research

RSS
Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Study reveals the intertumoral heterogeneity of METex14 skipping positive NSCLCs

Study reveals the intertumoral heterogeneity of METex14 skipping positive NSCLCs

Sub lobar surgery found to be non-inferior to lobectomy for patients with small-sized peripheral NSCLC

Sub lobar surgery found to be non-inferior to lobectomy for patients with small-sized peripheral NSCLC

Increased use of stereotactic body radiation therapy for NSCLC patients can reduce treatment disparities

Increased use of stereotactic body radiation therapy for NSCLC patients can reduce treatment disparities

New recommendations on how to determine eligibility criteria for lung cancer clinical trials

New recommendations on how to determine eligibility criteria for lung cancer clinical trials

Researchers report genomic profiling from more than 110,000 tumors

Researchers report genomic profiling from more than 110,000 tumors

Study: Certain genetic features predispose lung cancer patients to develop immunotherapy side effects

Study: Certain genetic features predispose lung cancer patients to develop immunotherapy side effects

Innovative strategy for treating non-small cell lung cancer when radiotherapy fails

Innovative strategy for treating non-small cell lung cancer when radiotherapy fails

Study provides better understanding of how therapeutic resistance develops in lung cancer

Study provides better understanding of how therapeutic resistance develops in lung cancer

Nanoparticles can be triggered to release anti-cancer microRNA using an alternating magnetic field

Nanoparticles can be triggered to release anti-cancer microRNA using an alternating magnetic field

New $5.3 million NIH grant will support researchers into understanding lung cancer recurrence

New $5.3 million NIH grant will support researchers into understanding lung cancer recurrence

MD Anderson announces collaborative alliance with Turning Point Therapeutics to advance new treatment options for cancer patients

MD Anderson announces collaborative alliance with Turning Point Therapeutics to advance new treatment options for cancer patients

New report estimates cancer prevalence in the U.S. and provides survivorship statistics

New report estimates cancer prevalence in the U.S. and provides survivorship statistics

Area-level education and income linked with patients' lung cancer stage at the time of diagnosis

Area-level education and income linked with patients' lung cancer stage at the time of diagnosis

Researchers identify predictive biomarkers to fight against non-small cell lung cancer

Researchers identify predictive biomarkers to fight against non-small cell lung cancer

New combination of drugs increases survival time for some patients with refractory lung cancer

New combination of drugs increases survival time for some patients with refractory lung cancer

Study: Nearly 43% of patients with KRAS-mutated lung cancer respond to experimental drug adagrasib

Study: Nearly 43% of patients with KRAS-mutated lung cancer respond to experimental drug adagrasib